| 前收市價 | 1.2000 |
| 開市 | 1.2300 |
| 買盤 | 1.1500 |
| 賣出價 | 1.6000 |
| 拍板 | 2.50 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 1.2000 - 1.2300 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
Insider MonkeyAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09. AKBA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the Akebia’s […]
ZacksAkebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BenzingaFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e
